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Hypopigmentation disorders that are associated with immunodeficiency feature both partial albinism of hair, skin and
eyes together with leukocyte defects. These disorders include Chediak Higashi (CHS), Griscelli (GS), Hermansky-Pudlak
(HPS) and MAPBP-interacting protein deficiency syndromes. These are heterogeneous autosomal recessive conditions
in which the causal genes encode proteins with specific roles in the biogenesis, function and trafficking of secretory
lysosomes. In certain specialized cells, these organelles serve as a storage compartment. Impaired secretion of specific
effector proteins from that intracellular compartment affects biological activities. In particular, these intracellular
granules are essential constituents of melanocytes, platelets, granulocytes, cytotoxic T lymphocytes (CTLs) and natural
killer (NK) cells. Thus, abnormalities affect pigmentation, primary hemostasis, blood cell counts and lymphocyte
cytotoxic activity against microbial pathogens. Among eight genetically distinct types of HPS, only type 2 is
characterized by immunodeficiency. Recently, a new subtype, HPS9, was defined in patients presenting with
immunodeficiency and oculocutaneous albinism, associated with mutations in the pallidin-encoding gene, PLDN.
Hypopigmentation together with recurrent childhood bacterial or viral infections suggests syndromic albinism. T and
NK cell cytotoxicity are generally impaired in patients with these disorders. Specific clinical and biochemical
phenotypes can allow differential diagnoses among these disorders before molecular testing. Ocular symptoms,
including nystagmus, that are usually evident at birth, are common in patients with HPS2 or CHS. Albinism with short
stature is unique to MAPBP-interacting protein (MAPBPIP) deficiency, while hemophagocytic lymphohistiocytosis (HLH)
mainly suggests a diagnosis of CHS or GS type 2 (GS2). Neurological disease is a long-term complication of CHS, but is
uncommon in other syndromic albinism. Chronic neutropenia is a feature of HPS2 and MAPBPIP-deficiency syndrome,
whereas it is usually transient in CHS and GS2. In every patient, an accurate diagnosis is required for prompt and
appropriate treatment, particularly in patients who develop HLH or in whom bone marrow transplant is required. This
review describes the molecular and pathogenetic mechanisms of these diseases, focusing on clinical and biochemical
aspects that allow early differential diagnosis.
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Hypopigmentation syndromes represent a readily distin-
guished group of diseases. Pigment dilution may involve
skin, hair and iris, and generally is manifest at birth.
Genetic defects of melanin biosynthesis are inherited as
autosomal recessive Oculocutaneous Albinism (OCA)
or X-linked Ocular Albinism (OA), in which abnormal
pigmentation is an isolated manifestation [1]. However,
hypopigmentation may also represent a feature of genetic
disorders characterized by immunodeficiency, including
Chediak Higashi Syndrome (CHS), Griscelli Syndrome
(GS), Hermansky-Pudlak type 2 Syndrome (HPS2) and
MAPBPIP-deficiency Syndrome. Recently a new form of
HPS-like syndrome, known as HSP-9, has been added
to the causes of immunodeficiency-associated albinism.
All causal genes that have been linked to albinism
appear to play a role in the biogenesis, function or traf-
ficking of intracellular organelles, particularly of secretory
lysosomes [2]. Cell types containing secretory lysosomes
include melanocytes, hematopoietic cells and renal tubular
cells. In melanocytes, secretory lysosomes are known as
melanosomes, and are involved in melanin pigment
secretion. Among cells of hematopoietic lineage, the
cytotoxicity of T and Natural Killer (NK) cells requires
tightly regulated secretion of cytolytic enzymes stored
in secretory lysosomes. In addition, antigen presenta-
tion to T cells by macrophages, dendritic cells and B
cells involves MHC-class-II positive secretory lysosomes
for proper transport and processing of endocytic antigens
[2]. Finally, primary hemostasis is mediated by platelet
clotting agents, stored in secretory lysosomes, while,
neutrophil antimicrobial activity depends upon regulated
release of cytosolic granules.
Defects in proteins involved in the function of secretory
lysosomes affect biological activity of these cells leading
to hypopigmentation and various degrees of immuno-
deficiency [3,4]. A thorough evaluation of a patient pre-
senting with partial albinism and immunodeficiency will
feature clinical, laboratory and molecular aspects aiming
to a prompt diagnosis and effective treatment.
Disease name
Partial Oculocutaneous Albinism and Immunodeficiency
(OCA-ID).
Definition
Partial Oculocutaneous Albinism and Immunodeficiency
(OCA-ID) is a group of five autosomal recessive syn-
dromes clinically characterized by hypopigmentation of
skin, hair and eyes, associated with recurrent infections.
While these diseases have similar cutaneous and ocular
manifestations, including partial albinism, nystagmus and
strabismus, the hematologic symptoms can be extremely
heterogeneous and vary from mild bleeding, as seen inHPS2 patients, to hemophagocytic syndrome, as observed
in CHS and GS2 patients. All patients with OCA-ID dis-
play a moderate to high susceptibility to both viral and
bacterial infections that can manifest variously as delayed
clearance of herpes viruses, and often by respiratory and
cutaneous bacterial infections. Defective cytotoxicity of
both NK and cytotoxic T cells (CTL) is observed in all
patients with OCA-ID, but to a variable extent, being
more severe in patients with CHS and GS2. Neutro-
penia is a chronic feature in HPS2 and in MAPBPIP-
deficiency, but can be transiently observed in the other
conditions [Table 1].
Epidemiology
Partial Albinism and Immunodeficiency disorders are ex-
tremely rare. Each of them has a prevalence of < 1/1,000,000
without crossover-enrichment in selected populations.
Patients presenting with oculo cutaneous albinism and
hemophagocytic lymphohistiocytosis
Hemophagocytic lymphohistiocytosis (HLH)
HLH represents a life-threatening condition commonly
affecting about 50-85% of CHS patients within the first
decade and, in the case of the majority of GS2 patients,
frequently in the first year of life [5,6]. A single case of
HLH has been reported in one patient with HPS2.
HLH is a severe hyperinflammatory disease caused by
uncontrolled but ineffective immune response. It is also
known as “accelerated phase”: it manifests as prolonged
fever, lymphadenopathy, hepatosplenomegaly, signs of
liver dysfunction (including jaundice, elevated transami-
nases, hypofibrinogenemia and/or hypertriglyceridemia,
high level of ferritin and lactate dehydrogenase), cytopenia
of at least two hematopoietic cell lineages (commonly
neutropenia, anemia, thrombocytopenia or pancytopenia)
[7]. Neurological manifestations, ranging from cranial nerve
palsy to seizures and decreased level of consciousness,
may occur. Cerebrospinal fluid shows pleocytosis, in-
creased proteins, or both [8]. Histopathology reveals
lymphoproliferative infiltration of bone marrow and retic-
uloendothelial system. The cause is a defective cytotoxic
activity leading to impaired down regulation of immune
response and sustained activation and proliferation of
CTL and NK cells [9]. These cells produce large amounts
of cytokines (such as IFNy, TNFalpha, GM-CSF) activat-
ing macrophages and dendritic cells. The latter migrate
to sites of inflammation, thus infiltrating tissues and
organs and producing high levels of proinflammatory
cytokines and chemokines that are responsible for the
laboratory signs and symptoms of HLH. Therefore, diag-
nosis is based on clinical and laboratory criteria, according
to the guidelines of the Hystiocyte Society lastly revised in
2007. For the diagnosis of HLH, five out of eight criteria
are required; they are: prolonged fever, enlarged spleen,















CHS CHS1 + + - + + +/-* + + +
GS2 RAB27A + - - - + +/-* + + -
HPS2 ADTB3A + + - - + + + + -
HPS9 PLDN + - - - - - + N/A -
MAPBPIP deficiency LAMTOR2 + - + - - + + + -
*Transient neutropenia can be observed.
CHS Chediak-Higashi syndrome; GS2 Griscelli syndrome type 2; HPS-2 Hermanski-Pudlak syndrome-type 2; HLH hemophagocytic lymphohistiocytosis.
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or more blood cell lineages, increased triglycerides or
reduced fibrinogen, increased serum ferritin, evidence
of hemophagocytosis in bone marrow but not malig-
nancy, abnormally high soluble CD25 in blood as sign
of T-cell activation.
Moreover, HLH may occur during the course of
Epstein-Barr virus infections, when it may resemble
lymphoma [10]. In patients who present with HLH as
the first manifestation of disease and with mild or ab-
sent symptoms of OCA-ID, other inherited forms of
HLH may be considered. Familial hemophagocytic lym-
phohistiocytosis is also genetically heterogeneous. There
are five genetically distinct types which share an auto-
somal recessive pattern of inheritance. The causal genes
are known for four types, and belong to the cytolytic
granule-dependent exocytosis pathway. They are per-
forin (FHL2), UNC13D (FHL3), syntaxin-11 (FHL4),
syntaxin-binding protein-2 (FHL5). In these cases, HLH
represents the primary and only manifestation of im-
munodeficiency [11]. If untreated, HLH may be fatal
within a few weeks. HSCT is strongly indicated as the
only curative treatment.
Chediak-higashi syndrome
CHS is an autosomal recessive disorder characterized by
partial albinism associated with immune dysfunction,
bleeding diathesis and progressive neurologic deterior-
ation. The risk of hemophagocytic lymphohistiocytosis
is estimated at 85% [5,12-14].
Clinical phenotype
Partial Albinism. Patients present a variable degree of
hypopigmentation affecting skin, hair and eyes [5,14].
Skin color can vary from milky-white to slate gray, and
hypopigmentation is often appreciated only by compari-
son with other family members. Skin hypopigmentation
is associated with increased risk of sun damage and skin
cancer; uncommonly, CHS may present with hyperpig-
mentation, leading to suspicion of other photosensitivity
diseases characterized by hyperpigmentation with con-
sequent delay in diagnosis [15]. Hair color may appear
blonde to light brown, often with a distinguished silveryor metallic sheen. Iris hypopigmentation may be associ-
ated with decreased retinal pigmentation, nystagmus and
impaired visual acuity.
Infections. The clinical history in CHS is typically re-
markable for recurrent and severe bacterial infections
since childhood [14]. Skin and respiratory tract are mainly
involved; Staphylococcus and Streptococcus are the species
most frequently isolated. Viral and fungal infections,
however, have also been described. According to recent
reports, severe periodontitis may also be an indication
to raise suspicion of CHS [16].
Bleeding diathesis. Patients present a prolonged bleed-
ing time and may manifest mildly disordered platelet ag-
gregation, including epistaxis, gum/mucosal bleeding,
petechiae, and easy bruising, that do not usually require
any treatment [5,14].
Neurological manifestations. Patients who survive into
early adulthood may develop motor and sensory neuropa-
thies, balance abnormalities, ataxia, tremor, absent deep-
tendon reflexes, and low cognitive abilities. In addition,
neurologic symptoms can also be observed in older
patients presenting with an atypical, milder form of CHS,
manifesting with dementia, parkinsonism, peripheral
neuropathy [5,14].
Molecular genetics and mechanisms
The human gene identified as causal for CHS, LYST/
CHS1, is located at chromosome 1q42.1-q42.2 [17-19].
LYST (lysosomal trafficking regulator) is a cytosolic pro-
tein of approximately 430 kDa which is highly conserved
through evolution and is expressed at low levels in all
cell types [20]. Its precise function remains unknown
but it is hypothesized its role in regulating lysosome size
and trafficking, particularly by regulating membrane
fission/fusion events [21,22]. The pathognomonic feature
of CHS is the presence of giant lysosomes and lysosome-
related organelles in all cell types [23,24]. While the
degradative function of lysosomes might be conserved,
the exocytic pathway of secretory lysosomes is impaired in
leukocytes of CHS patients. All mutations identified to
date are missense or nonsense substitutions, small coding
deletions or insertions that often result in protein trunca-
tion or nonsense mediated decay. A correlation between
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pothesized: loss-of-function mutations are associated with
severe, childhood-onset forms, while missense mutations
occur in milder adolescent- or adult-onset forms of the
disease [25,26]. In addition, other studies suggest a rela-
tion between the extent of the cellular defect and the
clinical phenotype [27]. Recently two novel heteroge-
neous mutations have been discovered, but their rela-
tionship with the clinical phenotype remains unclear
[28]. Each clinical manifestation of CHS is associated
with a defect of a specific cell type and to the formation
of secretory enlarged lysosomes in these cells [29-34].
Bleeding diathesis is related to the decreased pool of
platelet dense granules that is needed for a normal ag-
gregation response, while antimicrobial activity defect is
due to the reduced amount of neutrophil enzymes, as
well as the impaired exocytosis of lytic proteins is re-
sponsible for the impairment of NK and CTL cell cytotox-
icity. Pigment dilution is related to the defective migration
of giant melanosomes from the melanocyte dendrites to
surrounding keratinocytes. Therefore, the presence of giant
organelles may affect neutrophil chemotaxis and degranula-
tion as well as giant inclusions. In neuronal cells, formation
of giant granules might have a role in the pathogenesis
of the neurological manifestations of CHS patients.
Management
Episodes of infection, clinical and ophthalmological find-
ings may suggest the diagnosis of CHS. Clinical diagnosis
is firstly supported by the presence of peroxidase-positive
giant inclusions in white blood cells, by detection of pig-
ment clumping in the light microscopy analysis of hair
and eventually by studies revealing abnormal platelet
aggregation [14]. Electron microscopy can demonstrate
reduced number and irregular morphology of platelet
dense-bodies [29,30]. Of note, giant granules resembling
those seen in CHS may be revealed in acute and chronic
myeloid leukemia. NK cell counts are generally normal
but cytotoxic activity is impaired [33]. Neutropenia may
coexist with abnormal functioning (typically chemotaxis
and intracellular bactericidal activity) [32]. Immunoglobu-
lin levels, complement are generally normal while delayed
hypersensitivity may be impaired. Definitive diagnosis is
based on molecular genetic testing of LYST. Of note, cases
of neurological involvement, subtle albinism, bleeding
manifestations, even without history for recurrent infec-
tions, may be considered for atypical and mild pheno-
types of CHS [5]. Prognosis is poor because death
frequently occurs in the first decade of life due to infec-
tions or development of HLH. Treatment of infections
requires prompt and aggressive antimicrobial therapies;
while prophylaxis should be considered according to the
frequency of infectious episodes. A prompt diagnosis of
CHS can prevent the development of HLH by initiatingappropriate treatments. The most effective treatment
for the hematological and immune defects of CHS is
HSCT, albeit there is no evidence of efficacy in delaying or
preventing progressive neurological dysfunction [35,36].
Griscelli syndrome type 2
Griscelli syndrome is a rare autosomal recessive disorder
first described in 1978 as partial albinism associated with
immunodeficiency [37]. Type 2 Griscelli syndrome can
be distinguished from the other two forms of this dis-
order on the basis of distinctive clinical and molecular
features. Griscelli syndrome type 1 (GS1) features pri-
mary neurological disease and pigment anomalies and it
is caused by mutations in the MYO5A gene encoding
the motor protein myosin-Va [38]. The clinical features
of type 3 (GS3) are restricted to hypopigmentation of
skin, and hair. GS3 is caused by mutations in the
melanophilin gene MLPH [39]. Among GS subtypes, only
patients with type 2 commonly may develop HLH.
Clinical phenotype
Children with GS2 frequently present with silver-gray
hair and relatively light skin color. Usually they have
an increased susceptibility to recurrent pyogenic infec-
tions and may present with recurrent episodes of fever,
hepatosplenomegaly and lymphadenopathy [40]. In the
majority of GS2 patients, the development of HLH,
known also as the “accelerated phase”, occurs from 6
to 12 months of age [6]. While neurological symptoms
can be observed in GS2 patients, they are related to
the development of HLH in these subjects, as the gene
RAB27A associated with GS2 is not expressed in neur-
onal cells.
Molecular genetics and mechanisms
GS2 is caused by mutations in the RAB27A gene, which
maps to chromosome 15q21 and encodes a small GTPase
that regulates vesicular fusion and trafficking. In particular
Rab27a is required for peripheral anchorage of melano-
somes in melanocytes, as well as exocytosis of cytolytic
granules in CTL and NK cells. In addition, Rab27a is
crucial for docking of cytolytic granules to the plasma
membrane secondary to target-cell recognition and TCR
signal activation [6,41,42].
Management
Most commonly the diagnosis of GS2 occurs between
4 months and 7 years [40]. Parental consanguinity and
a history of familial deaths may be suggestive. Clinical
suspicion of GS2 can be supported by light microscopic
examination of hair shafts, typically showing irregular
large clumps of melanin pigment. Electron microscopic
evaluation of skin reveals numerous mature melano-
somes in melanocytes with few melanosomes in adjacent
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eral leukocytes. Defects of adaptive immunity are variable:
laboratory tests may reveal defective NK cytoxicity to-
gether with an impaired delayed-type hypersensitivity
response [41]. Commonly, however, granulocyte and
lymphocyte count and functions are normal, while im-
munoglobulin levels may be normal, decreased or in-
creased. As discussed below, since HLH typically develops
in GS2, the disease is fatal without HSCT [43,44]. Im-
munosuppressive therapy is reported to improve patient
symptoms as a palliative treatment or to induce remission
until HSCT can be performed [45]. There is evidence of
rescue of CTL activity using a retroviral vector to mediate
the transfer of RAB27A gene, opening an alternative pos-
sibility for GS2 treatment [46]. A prompt initiation of an
appropriate treatment can prevent complications, includ-
ing the neurological sequelae of the disease.
Patients presenting with oculocutaneous albinism
and neutropenia
Hermansky pudlak syndrome type 2 (HPS2)
HPS2 belongs to a genetically heterogenous group of
autosomal recessive disorders that share oculocutaneous
albinism and platelet storage disease. In humans, nine
causative genes have been cloned and sequenced: each
defective gene is involved in formation, transport or fu-
sion of intracellular vesicles of lysosomal lineage [47].
Type 2 represents the HPS type that was first associated
to immunodeficiency, specifically neutropenia.
Clinical phenotype
Clinical signs suggestive for HPS2 may be detectable at
birth [48]: they include horizontal nystagmus, ocular
hypopigmentation, including iris trans-illumination and
hypopigmentated areas of fundus oculi. As a conse-
quence, decreased visual acuity is frequent. Hair color
ranges from white to dark brown. Hair may be sparse
and white and may darken over time. In the same way,
skin varies from white to brown and often must be com-
pared to the skin tone of other family members to be
distinguished. As with other types of albinism, patients
are susceptible to sun damage and there is a higher risk
for skin malignancies. In childhood, distinctive facial
features may become evident, in particular, epicanthal
folds, posteriorly rotated ears, broad nasal root and
retrognathia. HPS2 patients may have a prolonged bleed-
ing time (up to > 15 minutes) and manifest spontaneous
soft tissue bruising and mucosal bleeding, while major
hemorrhages into joints, brain or other organs are rare.
Typically the first sign of a bleeding diathesis in HPS
patients consists of excess bruising beginning at the time
of first ambulation. Otherwise, episodes of epistaxis
are frequent but often remit during adolescence. Other
events that may result in excessive bleeding includedental extractions, surgeries, acute colitis, menstrual
periods, and childbirth. Recurrent infections are a promin-
ent feature of HPS2 [49]. Bacterial infections mainly
include upper respiratory infections, otitis media and
pneumonias. Moreover, HPS2 patients display higher
susceptibility to viral infections and certain malignan-
cies, such as Hodgkin’s lymphoma [50]. The defects of
cytotoxic activity that have been reported in HPS2 pa-
tients might suggest an increased risk of HLH. How-
ever, only one case of HLH in HPS2 has been described
in literature. That patient was also heterozygous for a
RAB27a mutation [51], suggesting that other genetic or
environmental factors probably contributed to HLH
development in this patient.
Molecular genetics and mechanisms
HPS2 is caused by mutations in AP3B1 gene, on chromo-
some 5q14.1, encoding the β3A subunit of the hetero-
tetrameric adapter protein (AP-) 3 complex [49,52]. Defects
in β3A subunit prevent the formation of the entire AP-3
complex. In mammalian cells there are 4 types of adaptor
protein complexes that are involved in cellular protein
trafficking. In particular, AP-3 directs post-translational
trafficking of intraluminal cargo proteins from the trans-
Golgi network to lysosomes [53-55]. The absence of the
AP-3 complex impairs trafficking of lysosome-targeted
proteins to and from lysosomes so that proteins trafficking
to lysosomes will accumulate at the plasma membrane.
Consequently, regulation and functioning of specific cells
related to secretory lysosomes are defective [56,57].
In melanosomes, there is evidence that AP-3 regulates
tyrosinase trafficking, which is essential for the synthesis
of melanin. In platelets, the absence of dense granules, that
contain ADP, ATP, serotonin, calcium and polyphosphates,
which are required for platelet aggregation, is a typical fea-
ture of the disease.
In neutrophils, AP-3 mediates trafficking of neutrophil
elastase to lysosome-like granules, known as azurophilic
granules. Neutrophil elastase is required for normal dif-
ferentiation of myeloid progenitor cells to mature neu-
trophils. Abnormal trafficking of neutrophil elastase is
associated with neutropenia, although the precise mech-
anism remains to be defined [58]. Thus, HPS2 patients
exhibit arrested maturation of neutrophil precursors
at the stage of pro-myelocytes. The neutrophil count in
HPS2 patients usually increases in response to infection
or to Granulocyte-Colony Stimulating Factor (G-CSF)
therapy [57,58].
In CTLs in HPS2, defects in lytic granule trafficking
and functioning are associated with impaired cytotox-
icity, particularly due to failure to secrete lysosomal lytic
enzymes, such as perforin and granzymes, in response
to receptor signaling [56,57]. Moreover, NK cells have
reduced lysosomal pools of perforin, while granzyme levels
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In addition, there is evidence for a role of the AP-3
complex in antigen presentation; notably AP-3 deficiency
results in impaired antigen presentation by CD1b and
impaired microbial lipid antigen presentation to T-cells
[59,60]. CD1b binding to AP-3 is required for proper
localization in the MHC class II compartment, for
appropriate sorting from the lysosome to the plasma
membrane and for antigen presentation. In particular,
there is a subset of T cells, known as invariant NK
T-cells (iNKT) expressing a semi-invariant TCR, which
confers the capacity to recognize a limited number of
glycosphingolipids presented by APCs in the context of
CD1b or of the murine ortholog CD1d [61,62]. As conse-
quence, these cells can play a stimulatory role toward
other immune cells or can exert immune regulatory
function. Lack of AP-3 might deregulate this signaling
and activation pathway contributing to NK-T cell defi-
ciency and to susceptibility to bacterial and viral infec-
tions [60,62].Diagnosis and management
Laboratory tests reveal neutropenia in HPS2 patients.
Platelet count is normal or increased but platelet aggre-
gation response is altered, generally with an abnormal
response to collagen and adenosine diphosphate, but nor-
mal response to ristocetin. Electron microscopy of platelets
reveals reduction of dense bodies. Lymphocyte subpopula-
tions and proliferative response to mitogens are generally
normal. NK cells and CTL cells are normal in number or
slightly reduced with an impaired cytolytic activity.
Molecular analysis of AP3B1 allows definitive diagno-
sis. A careful follow up is necessary to monitor when
G-CSF treatment is required.Hermansky pudlak syndrome type 9: pallidin deficiency
HPS9 is the most recently defined subtype of Hermansky-
Pudlak syndrome. It was recently described in patients
presenting with clinical manifestations suggestive of HPS,
but with negative molecular tests for previously known
HPS types [63]. The molecular basis of HPS9 in one of the
two pedigrees described was identified by exome sequen-
cing [64].Clinical phenotype
The two cases reported to date in the literature shared
partial albinism, nystagmus, normal neurological develop-
ment and absence of platelet delta granules, but lacked
the bleeding manifestations typical of HPS2 [63,64]. One
case had recurrent infections, especially of the skin, and
transient leukopenia [64].Molecular genetics and mechanisms
The two patients had the same homozygous mutation,
c.232C>T (p.Q78X), in exon 3 of the pallidin gene
(PLDN, chr15:45895305C>T), which led to undetectable
expression of the protein product in NK cells. The full
length PLDN transcript, which contains exon 3, is ubi-
quitously expressed in adult and fetal tissues with the
exception of brain. A second PLDN transcript, that has
a strong expression in the brain, arises as a result of al-
ternative splicing and skipping of exon 3, which con-
tains the mutation observed in the two HPS9 patients
[63]. Pallidin is a subunit of the protein complex BLOC-1
(biogenesis of lysosome-related organelles complex-1).
To date, mutations have been described in three human
BLOC-1 genes and in five mouse BLOC-1 genes. In
melanocytes, the absence of pallidin may impair the
stability and functioning of other BLOC-1 proteins such
as syntaxin-13, which is an endosome t-SNARE (target-
SNAP -Soluble N-ethylmaleimide-sensitive factor At-
tachment Protein- Receptor), and may alter intracellular
trafficking of TYRP1, a protein which is crucial for
melanosome maturation and melanin production [63].
In NK cells, pallidin regulates the expression of lyso-
somal membrane proteins, particularly CD107a and
CD63, akin to HPS2. It has been shown that pallidin
absence results in impairment of degranulation and
cytolytic activity of NK cells thus leading to immune
defects [64].
Management
HPS9 may be suspected together with HPS2 in patients
with albinism and recurrent infections; although the two
HPS9 patients did not present bleeding manifestations,
further cases are needed to more fully define the clinical
phenotype. Antibiotic prophylaxis can be used in patients
with recurrent infections.
Deficiency of endosomal adaptor protein MAPBPIP
A recently defined primary immunodeficiency syn-
drome features congenital neutropenia and B-cell and
CTL deficiency together with partial albinism and short
stature [65].
Clinical phenotype
The reports to date in the literature describe children
with recurrent bronchopulmonary infections, mainly by
Streptococcus pneumonia, with the short stature as an
additional pathognomonic feature [65]. The extent of
albinism is variable.
Molecular genetics and mechanisms
MAPBPIP, is encoded by the LAMTOR2 gene, is an ubiqui-
tous endosomal protein (also known as p14). It is localized
on the outer membrane of late endosome, and functions
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tein kinase (MAPK) signaling [66,67]. MAPBPIP plays an
essential role in many cellular functions such as subcellu-
lar compartmentalization of signals and cellular responses
to cell surface receptor signaling, as evidenced by early
lethality in Lamtor2 knock-out mice [65]. A homozy-
gous point mutation in the 3’UTR of LAMTOR2 located
on chromosome 1q21 causes decreased LAMTOR2 mRNA
expression and consequently decreased protein levels.
Aberrant lysosome function due to MAPBPIP deficiency
affects neutrophils, B cells, CTLs and melanocytes. Neu-
trophils show an altered ultrastructure of azurophilic gran-
ules and decreased microbiocidal activity in phagosomes. In
MAPBPIP-deficient cells, cytokine-receptor-mediated ERK
phosphorylation is defective and a marked delocalization
of late endosomes can be observed.
Management
Recurrent bacterial infections and growth delay in a pa-
tient affected by severe peripheral neutropenia may be
suggestive for this new form of OCA-ID. Neutrophil
maturation in bone marrow is supposed to be preserved.
To date, in MAPBPIP deficiency syndrome immuno-
logical tests reveal decreased CTL cytotoxicity, and in-
creased number of naïve B cells but a reduced number
of memory B cells [65]. Definitive diagnosis depends on
molecular analysis demonstrating mutations in MAPBPIP
gene. Treatment with G-CSF is required to reduce fre-
quency and severity of infections.
Differential diagnosis
Hypopigmentation of skin, hair and eyes can be easily
observed at birth in the majority of patients with
oculocutaneous albinism, while the degree of hypopig-
mentation is variable, often according to parent’s pigmen-
tation. Depigmentation is commonly extensive in HPS2
and CHS patients and affects skin, coloring from white
to gray, hair, tingling from blonde to light brown, or
with a silvery or metallic sheen typical of CHS, and eyes
appearing gray, blue or rarely brown [5,48]. In GS2,
hypopigmentation affects skin and hair, which is typically
silvery-gray [41], while in MAPBPIP deficiency albinism
is variable and the pathognomonic sign is the short stature
[65]. Ocular symptoms, particularly nystagmus, iris trans-
lucency and reduced retinal pigmentation, are similarly
present in neonates, in patients with CHS or HPS2. Symp-
toms related to immunodeficiency usually become evident
in childhood and therefore, at birth, the phenotype of
OCA-ID disorders cannot be easily distinguished from
other causes of albinism [1]. Similar ocular and cutane-
ous features can be found in patients with Hermansky-
Pudlak syndromes (HPS1-8), but these patients may also
have mild bleeding defects and, at later ages, interstitial
pulmonary fibrosis. Other rare inherited disordersthat should be excluded in patients with albinism are
Waardenburg Syndrome type II (WS2), which is associated
with sensor-neural deafness, and Griscelli syndrome type 1,
which is also characterized by neurological disorders
and by a unique distribution of pigment in hair. Although
differential diagnosis of OCA-ID within these inherited
disorders can be easy at later ages, after observation of
repeated episodes of infections, the diagnosis should not
be delayed if OCA-ID is suspected because invasive in-
fections may be fatal in such patients. Moreover, neuro-
logical symptoms appear along time in CHS patients,
being characterized mainly by peripheral neuropathy [14].
HLH occurs primarily in CHS and GS2 [5,6]. Only one
case of HLH has been reported in HPS2 [51]. Given the
limited number of cases, it is impossible to define the
risk of HLH in patients with p14 or pallidin deficiency.
HLH is a life threatening condition that may be prevented
with the appropriate treatment when diagnosis is defined.
Therefore, when one of these disorders is suspected,
microscopic, immunological and genetic studies should
be promptly performed.
In CHS, microscopic evaluation of hair shafts reveals
regular small melanin aggregates, while in GS2 irregular
large clumps of melanin pigment are characteristic. More-
over, microscopic evaluation of skin shows in CHS giant
melanosomes both in keratinocytes and melanocytes;
while in GS2, epidermal melanocytes are filled with nu-
merous mature melanosomes and adjacent keratinocytes
with only rare melanosomes. Evaluation of neutrophil
organelle morphology and count is useful in CHS, HPS2
and MAPBPIP deficiency, but unrevealing in GS2. Neu-
tropenia is chronic in HPS2 and MAPBPIP deficiency,
while it can be transiently observed in CHS and GS2.
Neutrophil functions, including bactericidal activity, chemo-
taxis and degranulation, are defective only in CHS, where
microscopic examination of peripheral blood smear re-
veals giant inclusions that are typical of this disorder [24].
For prompt identification of OCA-ID, evaluation of NK or
CTL cytotoxic activity against susceptible cells is import-
ant, because it is impaired in all these syndromes. Im-
munoglobulin levels are typically normal in HPS2 and
CHS patients, while in GS2 immunoglobulin may be in-
creased or reduced. In MAPBPIP deficiency, B-memory
cells are reduced, with consistently decreased serum IgM
levels [65]. In CHS and GS2, delayed hypersensitivity may
be impaired, while no alterations are described in the
other syndromes [14]. Functional platelet studies reveal
defects in aggregation, while their count is normal or in-
creased in HPS2 and CHS. Molecular genetic testing is
the gold standard for definitive diagnosis. Newer ap-
proaches, such as genome, exome or gene panel sequen-
cing, are starting to be employed for differential diagnosis
of disorders such as these, where there is substantial gen-
etic heterogeneity [68-76].
Figure 1 Diagnostic approach to patients with oculocutaneous albinism.
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All five types of OCA-ID share an autosomal recessive
pattern of inheritance. Therefore, the parents of a child
with any of these conditions are usually obligate carriers
of the disease and are asymptomatic. The risk of recur-
rence in a family with an affected child is 25%. Although
consanguinity may be suggestive, meanwhile, many cases
are sporadic and family history may be negative.
Carrier detection and prenatal diagnosis are possible
by molecular analysis of the causative gene after identifi-
cation of the genetic mutation in the proband (affected
individual). For prenatal diagnosis, genetic testing can
be performed on DNA extracted from a chorionic villus
sample (CVS) at 10–12 weeks gestation or cultured
amniocytes. In principle, preimplantation diagnosis by
molecular genetic analysis would be feasible following
identification of the causative mutation(s) in the proband.
Conclusion
Differential diagnosis of Chediak-Higashi syndrome, Griscelli
syndrome type 2, Hermansky-Pudlak syndrome type 2
and type 9 and MAPBPIP deficiency syndrome requires
clinical, biochemical and molecular criteria. Clinical suspi-
cion of OCA-ID should promptly lead to the performanceof laboratory tests, including blood cell counting, blood
smear analysis and immunoglobulin levels. In addition,
clinical investigation of these patients should include
assessment of NK or CTL cytotoxicity activity, light
microscopic evaluation of hair and ophthalmological
studies [Figure 1]. Finally, defining the causal genetic
mutation may allow prompt institution of the appropriate
treatments in affected patients and promote molecular
tests in family members when necessary.
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